logo-loader
viewScancell Holdings PLC

Full interview: Scancell back in the clinic with a phase II trial of its flagship skin cancer treatment

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment.

The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s checkpoint inhibitor Keytruda.

Quick facts: Scancell Holdings PLC

Price: 5.65 GBX

LSE:SCLP
Market: LSE
Market Cap: £26.29 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Next Green Wave sees impressive revenue numbers as the company becomes...

Next Green Wave (CSE: NGW- OTCQX: NXGWF) CEO Mike Jennings joined Steve Darling from Proactive Vancouver with news the company has released very positive financial number that has seen them become profitable in the last 3 months. Jennings talks about what has led the company to that milestone...

10 hours, 4 minutes ago

2 min read